The Bifurcation Is Here
Where biotech capital is actually going in 2026 — and what it means if you’re raising.
Everyone in biotech is talking about the recovery. The rounds are closing. The press releases are back. The tone has shifted from survival to momentum. But look at where the money is actually going — not where founders say it is, not where VCs say they’re focused — and a different picture emerges. The recovery is real. It’s just not evenly distributed. Not even close.
THE NUMBERS
Series D deal value rose 60x from Q2 to Q3 2025 — the steepest growth of any round stage in this period. That’s not a rounding error. That’s a structural reallocation.
This month, Angitia Biopharmaceuticals closed a $130M Series D backed by more than 15 institutional investors — including BlackRock, RA Capital, and Wellington. That’s not a single bullish firm making a contrarian bet. That’s a coordinated institutional signal: capital is moving toward later-stage assets with clinical proof, and it’s doing so at scale.
Meanwhile, early-stage deal volume is up 18% year-over-year. But average check sizes are shrinking. More companies are raising. The same pool of early-stage capital is being divided into smaller pieces. The number looks good. The math doesn’t.
WHY IT HAPPENED
The 2021-2023 correction burned investors who had moved early and fast. Seed and Series A bets that looked like category-defining platforms in a zero-interest-rate environment became expensive lessons in clinical risk and burn rate. The response was predictable: GPs tightened their deployment criteria, LPs pushed for de-risked assets, and the definition of “investable” moved several clinical milestones further down the road.
What we’re seeing now isn’t a recovery across the board. It’s a flight to proof. Investors aren’t abandoning biotech — they’re consolidating into it at the stage where risk has already been absorbed by someone else. The result is a market where the later you are, the better your terms. The earlier you are, the harder you’re fighting for a check that’s gotten smaller.
WHAT IT MANES FOR FOUNDERS
If you're raising a Seed or Series A right now, you're operating in a fundamentally different capital environment than the headline data suggests. The aggregate numbers — deal count, total capital deployed — obscure a bifurcation that the individual founder feels acutely.
The practical reality: early-stage investors are being more selective, moving more slowly, and syndicating more cautiously than they were 18 months ago. Valuation expectations that felt conservative in 2023 are being pushed down further. Bridge rounds that were once an afterthought are now structural features of early-stage company building.
None of this is fatal. But founders who are calibrating their expectations against the macro narrative — "biotech is back" — rather than the actual behavior of capital at their stage are going to find themselves surprised. The market is back. Just not for everyone, and not yet at every stage.
WHAT MOLECULE IS WATCHING
The next signal to track is whether late-stage momentum starts pulling early-stage capital behind it — or whether the bifurcation hardens into a structural feature of the market. Historically, a sustained Series C/D boom creates downstream pressure on earlier stages as VCs rebuild their pipelines. That rotation typically lags by 12–18 months.
We're also watching thematic concentration. The large rounds closing right now aren't evenly distributed across therapeutic areas. They're clustering. Where they cluster tells you where institutional conviction is building — and where the next wave of early-stage capital will likely follow.
That's what we'll be tracking next.
